Quantum Health Names Scott Doolittle as Chief Financial Officer

Columbus, OH May 23, 2016 – Quantum Health, Inc. announced Scott Doolittle as Chief Financial Officer.
Doolittle will lead Financial Operations, Business Intelligence and Business Planning, with day-to-day responsibilities that include executing financial strategy, providing decision support for key business initiatives, and strengthening customer reporting capabilities. He will also support new product initiatives, as well as maintain key relationships with external partners. His experience will provide critical strategic leadership during this time of rapid growth for Quantum Health.
“Scott is a true leader in healthcare, whose expertise and knowledge of the evolving healthcare industry will be instrumental to our continued growth and success,” said Kara Trott, Founder and Chief Executive Officer of Quantum Health.
Prior to joining Quantum Health, Doolittle served as Senior Vice President of Finance and Operations for Healthways, the largest global provider of population health and well-being improvement solutions.
Doolittle holds a Bachelor’s of Science in Finance from Miami University and Master of International Business Studies from the University of South Carolina.
About Quantum Health
Quantum Health is an award-winning care coordination and consumer navigation company serving the needs of self-insured public and private employers across the United States since 1999. With a background in consumer behavior and a deep understanding of how real people experience healthcare, Quantum Health has a proven history of improving the efficiency of clients’ benefits plans while maintaining industry-leading satisfaction rates and claims savings. Based in Columbus, Ohio, Quantum Health has been recognized on the Inc. 5000 as one of the fastest-growing privately held companies for the past seven consecutive years (2008-2015), listed as one of the 50 Fastest Growing Women Owned/Led Companies by the Women Presidents’ Organization and has been listed as both a FORTUNE Magazine Great Place to Work® and an Entrepreneur Magazine Great Place to Work®. Learn more at Quantum-Health.com, and connect with us on Twitter (@QuantumHealth1), and LinkedIn (Company: Quantum Health).

Founder and CEO of Quantum Health asked to join the National Leadership Committee on Consumerism and Engagement to Improve Employee Health Care

Columbus, OH May 13, 2016 – Quantum Health Founder and Chief Executive Officer, Kara Trott, announced today that she is honored to accept an invitation to collaborate with top business executives and health care leaders from around the country in an exciting opportunity to improve employee health care.
The National Leadership Committee on Consumerism and Engagement (NLCCE), established by the National Business Group on Health (NBGH), in a mission to provide a leadership forum focusing on (1) finding and evaluating effective solutions to the health care benefits challenges of large employers, (2) identifying and disseminating best practices and innovative ideas for empowering and engaging employees and their dependents in the health care process, (3) identifying gaps in effective programs and practices and influencing industry to fill the gaps, (4) promoting effective public polices, and (5) promoting individual accountability and consumerism in all types of plans and financing methods.
Members of the committee include executives from some of today’s largest corporations, as well as key influencers in the health care industry.
“I am excited and honored to join such an esteemed group of executives and industry leaders,” said Trott. “Participating in the NLCCE is a unique opportunity to collaborate with key stakeholders to develop solutions and strategies that will help improve health care delivery and make it more cost-effective for payers, employers and participants.”
About Quantum Health
Quantum Health is an award-winning care coordination and consumer navigation company serving the needs of self-insured public and private employers across the United States since 1999. With a background in consumer behavior and a deep understanding of how real people experience healthcare, Quantum Health has a proven history of improving the efficiency of clients’ benefits plans while maintaining industry-leading satisfaction rates and claims savings. Based in Columbus, Ohio, Quantum Health has been recognized on the Inc. 5000 as one of the fastest-growing privately held companies for the past seven consecutive years (2008-2015), listed as one of the 50 Fastest Growing Women Owned/Led Companies by the Women Presidents’ Organization and has been listed as both a FORTUNE Magazine Great Place to Work® and an Entrepreneur Magazine Great Place to Work®. Learn more at Quantum-Health.com, and connect with us on Twitter (@QuantumHealth1), and LinkedIn (Company: Quantum Health).
About NBGH
The National Business Group on Health is the nation’s only non-profit organization devoted exclusively to representing large employers’ perspective on national health policy issues and helping companies optimize business performance through health improvement, innovation and health care management. The Business Group leads initiatives to address the most relevant health care issues facing employers today and enables human resource and benefit leaders to learn, share and leverage best practices from the most progressive companies. Business Group members, which include 71 Fortune 100 companies, provide health coverage for more than 50 million U.S. workers, retirees and their families. For more information, visit www.businessgrouphealth.org.

Cold Chain Solution Provider CSafe Global Appoints Sébastien Berrous as Sales Director, France and Spain

Dayton, OH May 5, 2016 – CSafe Global, a world leader in performance cold-chain solutions for the life sciences sector, announced it has appointed Sébastien Berrous as Director of Sales for France and Spain, where the company enjoys a rapidly expanding market presence.
As part of a vigorous expansion drive which is seeing CSafe Global open new operational service centres around the world to support the rapidly growing needs of life science customers, Sébastien Berrous will be responsible for the company’s overall business in France and Spain. “Sébastien brings a wealth of medical sales leadership experience to our European team and will be instrumental in helping many of the top biopharmaceutical companies in Europe solve their most pressing high risk cold chain challenges. His experience driving strategic market development excellence in senior roles at GE Healthcare and most recently at B. Braun, as France’s Managing Director of Inkospor branch, prepares Sebastien to best serve the market value priorities in France and Spain. We are very pleased to have Sebastien join the team and have every confidence in his market growth expertise as we continue to expand these important markets in Europe,” comments Nadine Siqueland, CSafe Vice President of Global Sales.
CSafe solutions are used for the protection of temperature-sensitive biopharmaceutical products and provide life science companies with the necessary margin of safety when it comes to protecting medicines during their long journey from producer to consumer. France is a major market for pharmaceuticals. It is Europe’s fourth largest producer, third largest importer, fourth largest exporter and second largest consumer. Spain is Europe’s fourth largest pharma employer and sixth in terms of both production and consumption. Taken together the two countries constitute Europe’s biggest concentration of pharma production.
Commenting on joining CSafe, Sebastien Berrous stated: “This is a very exciting time to be joining CSafe Global which stands out in the pharma-logistics sector as a dynamic, innovative and customer-centric company. I am looking forward to building on the successes already achieved and growing CSafe’s biopharmaceutical base in France and Spain.”

Quantum Health Welcomes New Manager of Pharmacy Services, Kelly Kaufman

Columbus, OH May 4, 2016 – Quantum Health Inc., a leader in care coordination and consumer navigation, announces today the addition of Kelly Kaufman to their clinical team as Manager of Pharmacy Services. She will provide pharmaceutical expertise in support of Quantum Health’s internal clinical staff as well as Quantum Health’s members.
Kelly will be an integral part as Quantum Health continues to expand their pharmacy and medication expertise, along with strengthen their relationships with PBM vendor partners as the healthcare landscape continues to evolve.
“We’re thrilled Kelly has joined our team,” says Chief Medical Officer, Dr. Dana Andrews, MD. “Her extensive pharmaceutical knowledge and experience will be invaluable in our mission to provide our consumers and clients with an exceptional healthcare experience.”
Kaufman’s career spans more than 10 years in the pharmacy and pharmacy benefits industry. Most recently, she served as Clinical Pharmacy Liaison at Helios, a pharmacy benefits management company, where she implemented clinical programs to assist clients with managing claims and reducing costs.
Kaufman is an alumna of Ohio Northern University, where she earned a BS in pharmacy. She currently holds active pharmacy licenses in Ohio, Kentucky, and Pennsylvania.
About Quantum Health
Quantum Health is an award-winning care coordination and consumer navigation company serving the needs of self-insured public and private employers across the United States since 1999. With a background in consumer behavior and a deep understanding of how real people experience healthcare, Quantum Health has a proven history of improving the efficiency of clients’ benefits plans while maintaining industry-leading satisfaction rates and claims savings. Based in Columbus, Ohio, Quantum Health has been recognized on the Inc. 5000 as one of the fastest-growing privately held companies for the past seven consecutive years (2008-2015), listed as one of the 50 Fastest Growing Women Owned/Led Companies by the Women Presidents’ Organization and has been listed as both a FORTUNE Magazine Great Place to Work® and an Entrepreneur Magazine Great Place to Work®. Learn more at Quantum-Health.com, and connect with us on Twitter (@QuantumHealth1), and LinkedIn (Company: Quantum Health).

HealthTronics Announces AUA2016 Presentations

Austin, TX May 3, 2016 – HealthTronics Inc., a leading provider of mobile medical technologies, announced that AUA2016, the American Urological Association annual meeting to be held May 6-10 in San Diego, California, will include 11 presentations from world-wide experts to help urologists increase their knowledge of appropriate use and follow up for prostate and kidney cryoablation.
Cryoablation is a technology that uses small ice crystals to kill cancer cells with extreme cold. Endocare, Inc., a subsidiary of HealthTronics, Inc., manufactures the leading cryotherapy treatment devices for urologic applications. For more information on cryoablation, visit www.StopCancerCold.com.
“As cryotherapy plays an increasingly important role in urologic medicine, HealthTronics is committed to working with urology leaders to further groundbreaking research and the advancement of prostate and kidney cancer treatments,” said Russell Newman, HealthTronics’ president.
The AUA2016 cryotherapy presentations are:

  • “Post-Salvage Therapy, Particularly with Nadir PSA<1, Delays the Time to Subsequent Androgen Deprivation Therapy.” Abstract number: MP14-05
  • “Predictors of Local Disease Control After Salvage Whole Gland Prostate Cryoablation.” Abstract number: MP18-03
  • “Whole Gland Salvage Cryoablation of Prostate: Long-Term Oncological Outcomes.” Abstract number: MP18-04
  • “Evaluation of Urinary Function After Cryoablation of the Prostate.” Abstract number: MP18-12
  • “Comparisons of Oncological and Functional Outcomes Among Radical Retropubic Prostatectomy, High Dose Rate Brachytherapy, Cryoablation and High-intensity Focused Ultrasound for Localized Prostate Cancer: A Prospective, Controlled, Nonrandomized Trial.” Abstract number: MP18-17
  • “Comparison of Contrast-Enhanced Ultrasound Scan (CEUS) and MRI in the Follow-up of Cryoablation for Small Renal Tumors. Experience with 80 Cases.” Abstract number: MP19-05
  • “Percentage of Renal Parenchymal Preservation and Renal Tumor Morphology are Determinants of Renal Functional Outcome Following Percutaneous Cryoablation.” Abstract number: S&T-02
  • “Cryoablation versus Partial Nephrectomy for Clinical T1b Tumors: A Matched Group Analysis.” Abstract number: MP64-04
  • “Comparison of Radiation Dosages Between CT-Guided and Ultrasound-Facilitated CT-Guided Percutaneous Cryoablation of Small Renal Cortical Neoplasms.” Abstract number: PD46-01
  • “Evaluation of Skin-to-Tumor Distance as a Predictor of Tumor Recurrence Following Percutaneous Cryoablation of Renal Cortical Neoplasms.” Abstract number: PD46-03
  • “Salvage Percutaneous Cryoablation for Locally Recurrent Renal Cell Carcinoma After Primary Cryoablation.” Abstract number: PD46-05

Additional information can be found at www.aua2016/abstracts.